Sanara MedTech

Sanara MedTech

Sanara MedTech incorporated in Texas and is headquartered in Fort Worth. Ronald T. Nixon leads the firm as Chairman and CEO. The company focuses on advanced wound care and surgical repair, developing and distributing products used in a range of surgical settings. Its primary commercial strategy bypasses the traditional direct-sales model in favor of exclusive distribution agreements with independent sales agencies across the United States. The firm's product portfolio includes biomatrix soft-tissue repair grafts, bone-graft substitutes, and negative-pressure wound therapy systems designed for use in general surgery, orthopedics, and women's health. Sanara's distribution model allows it to scale geographically without the fixed cost of a large employed salesforce; the network covers hospitals and outpatient surgery centers in multiple US regions. The company has acquired or licensed technology to expand its clinical footprint, including products cleared by the FDA for specific surgical indications. In 2023, Sanara launched a strategic partnership with a major hospital network to evaluate its surgical technologies in a multi-site clinical study (per the firm, October 2023). Sanara operates additional business units that extend its reach beyond product sales. TEAM Technologies, a wholly owned subsidiary, provides contract manufacturing and packaging for medical device companies. A separate division, Sanara Ventures, manages investments in early-stage healthcare companies with technologies that supplement the core surgical business. In May 2024, the company disclosed a new investment in a biologics startup working on next-generation skin substitutes, a move consistent with its focus on surgical tissue repair, May 2024). The firm's structure as a publicly traded operating company with a captive manufacturing arm and a venture-investing subsidiary sets it apart from most wound-care businesses. Each unit feeds the others: the manufacturing subsidiary can support portfolio companies, while Sanara Ventures scouts technologies that could eventually move through the company's existing hospital distribution channel. This design creates an internal pipeline from early-stage innovation to clinical use without relying on external acquirers to commercialize new products.